Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 256

1.

A critique of the dopamine hypothesis of schizophrenia and psychosis.

Moncrieff J.

Harv Rev Psychiatry. 2009;17(3):214-25. doi: 10.1080/10673220902979896. Review.

PMID:
19499420
2.

Psychosis pathways converge via D2high dopamine receptors.

Seeman P, Schwarz J, Chen JF, Szechtman H, Perreault M, McKnight GS, Roder JC, Quirion R, Boksa P, Srivastava LK, Yanai K, Weinshenker D, Sumiyoshi T.

Synapse. 2006 Sep 15;60(4):319-46. Review.

PMID:
16786561
3.

Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men.

Boileau I, Dagher A, Leyton M, Gunn RN, Baker GB, Diksic M, Benkelfat C.

Arch Gen Psychiatry. 2006 Dec;63(12):1386-95.

PMID:
17146013
4.

Serotonin and dopamine interactions in psychosis prevention.

Richtand NM, McNamara RK.

Prog Brain Res. 2008;172:141-53. doi: 10.1016/S0079-6123(08)00907-2. Review.

PMID:
18772031
5.

Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations.

Maas JW, Bowden CL, Miller AL, Javors MA, Funderburg LG, Berman N, Weintraub ST.

Schizophr Bull. 1997;23(1):147-54.

6.

Beyond the dopamine hypothesis. The neurochemical pathology of schizophrenia.

Reynolds GP.

Br J Psychiatry. 1989 Sep;155:305-16. Review.

PMID:
2692761
7.

Stimulant-induced psychosis and schizophrenia: the role of sensitization.

Ujike H.

Curr Psychiatry Rep. 2002 Jun;4(3):177-84. Review.

PMID:
12003679
8.

The relationship between epilepsy and schizophrenia: a biochemical hypothesis.

Trimble M.

Biol Psychiatry. 1977 Apr;12(2):299-304.

PMID:
15665
10.

Stimulant psychosis: systematic review.

Curran C, Byrappa N, McBride A.

Br J Psychiatry. 2004 Sep;185:196-204. Review.

11.

[A biochemical theory of schizophrenia].

Kornhuber HH, Kornhuber J, Kim JS, Kornhuber ME.

Nervenarzt. 1984 Nov;55(11):602-6. German.

PMID:
6151120
12.

Biochemistry and the schizophrenia. Old concepts and new hypothesis.

Berger PA.

J Nerv Ment Dis. 1981 Feb;169(2):90-9. Review.

PMID:
7009786
13.

Therapeutic possibilities of cysteamine in the treatment of schizophrenia.

Pae CU, Lee C, Paik IH.

Med Hypotheses. 2007;69(1):199-202. Epub 2006 Dec 12.

PMID:
17166669
14.

[The n-3 fatty acid/dopamine hypothesis in schizophrenia].

Ohara K.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2006 Aug;26(4):149-53. Review. Japanese.

PMID:
17020131
15.

Neural basis of psychosis-related behaviour in the infection model of schizophrenia.

Meyer U, Feldon J.

Behav Brain Res. 2009 Dec 7;204(2):322-34. doi: 10.1016/j.bbr.2008.12.022. Epub 2008 Dec 30.

PMID:
19154759
16.

[Investigation of the dopamine dysregulation hypothesis of schizophrenia with neuroimaging techniques].

Szekeres G, Pávics L, Janka Z.

Ideggyogy Sz. 2002 Jul 20;55(7-8):226-32. Review. Hungarian.

PMID:
12201230
17.

Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence.

Hornykiewicz O.

Neuroscience. 1978;3(9):773-83. Review. No abstract available.

PMID:
30919
18.
19.

Are dopamine D2 receptors out of control in psychosis?

Seeman P.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Oct 1;46:146-52. doi: 10.1016/j.pnpbp.2013.07.006. Epub 2013 Jul 21. Review.

PMID:
23880595
20.

The n-3 polyunsaturated fatty acid/dopamine hypothesis of schizophrenia.

Ohara K.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):469-74. Epub 2006 Dec 20. Review.

PMID:
17184889
Items per page

Supplemental Content

Write to the Help Desk